AbbVie Inc. $ABBV Stock Holdings Decreased by Patten & Patten Inc. TN

Patten & Patten Inc. TN lessened its stake in shares of AbbVie Inc. (NYSE:ABBV) by 1.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 171,125 shares of the company’s stock after selling 2,568 shares during the quarter. AbbVie comprises approximately 2.3% of Patten & Patten Inc. TN’s portfolio, making the stock its 7th biggest position. Patten & Patten Inc. TN’s holdings in AbbVie were worth $39,622,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. BLB&B Advisors LLC grew its position in AbbVie by 0.3% in the 3rd quarter. BLB&B Advisors LLC now owns 87,556 shares of the company’s stock valued at $20,273,000 after buying an additional 269 shares during the last quarter. Sagespring Wealth Partners LLC lifted its stake in shares of AbbVie by 12.4% in the 3rd quarter. Sagespring Wealth Partners LLC now owns 38,051 shares of the company’s stock worth $8,810,000 after acquiring an additional 4,192 shares during the period. Mendel Capital Management LLC lifted its stake in shares of AbbVie by 1.5% in the 3rd quarter. Mendel Capital Management LLC now owns 7,746 shares of the company’s stock worth $1,794,000 after acquiring an additional 115 shares during the period. Global Assets Advisory LLC boosted its holdings in shares of AbbVie by 9.8% in the third quarter. Global Assets Advisory LLC now owns 6,869 shares of the company’s stock valued at $1,591,000 after acquiring an additional 612 shares in the last quarter. Finally, Biltmore Family Office LLC increased its stake in shares of AbbVie by 10.8% during the third quarter. Biltmore Family Office LLC now owns 34,925 shares of the company’s stock worth $8,086,000 after acquiring an additional 3,408 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on ABBV shares. Piper Sandler reaffirmed an “overweight” rating and issued a $289.00 price objective (up previously from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Morgan Stanley raised their price target on AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Hsbc Global Res raised AbbVie from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 10th. Guggenheim increased their price objective on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research report on Monday, October 20th. Finally, DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price on the stock. in a research report on Tuesday, November 4th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus price target of $248.11.

AbbVie Stock Up 0.5%

Shares of ABBV stock opened at $219.21 on Friday. The stock has a market cap of $387.42 billion, a P/E ratio of 166.07, a P/E/G ratio of 0.90 and a beta of 0.36. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The business has a fifty day simple moving average of $225.60 and a 200-day simple moving average of $217.41.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same period in the prior year, the company earned $3.00 EPS. The firm’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, sell-side analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is presently 524.24%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.